Aethlon CEO Discusses Bioweapon Treatment Program
May 04 2005 - 2:41PM
Business Wire
Aethlon Medical, Inc. (OTCBB:AEMD) announced that its Chairman
& CEO, James A. Joyce was interviewed by The Wall Street
Reporter today. Mr. Joyce discussed Aethlon's strategy for treating
biological weapons and described how the Company's Hemopurifier(TM)
treatment technology is positioned to be the first line of defense
against several drug and vaccine resistant bioweapons. Mr. Joyce
also indicated that pre-clinical blood studies have demonstrated
the effectiveness of the Hemopurifier in capturing pox viruses
related to Smallpox. The interview can be accessed at
www.wallstreetreporter.com through Friday, May 6th. About Aethlon
Medical Aethlon Medical is pioneering the development of viral
filtration devices to treat drug and vaccine resistant pathogens.
The market focus is the treatment of the Human Immunodeficiency
Virus (HIV), Hepatitis-C (HCV), and Biological Weapon candidates.
Aethlon has an experienced management team, which receives support
and guidance from globally recognized science advisors representing
the infectious disease, biowarfare, and dialysis industries.
Clinical Trials to treat HIV and HCV patients in India are
scheduled to begin in the coming months, and U.S. clinical studies
are expected to begin later this year. More information on Aethlon
Medical and the Hemopurifier technology is available at
www.aethlonmedical.com. Certain of the statements herein may be
forward-looking and involve risks and uncertainties. Such
forward-looking statements involve assumptions, known and unknown
risks, uncertainties and other factors which may cause the actual
results, performance or achievements of Aethlon Medical, Inc to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such potential risks and uncertainties include, without
limitation, the Company's ability to raise capital when needed, the
Company's ability to complete the development of its planned
products, the ability of the Company to obtain FDA and other
regulatory approvals permitting the sale of its products, the
Company's ability to manufacture its products and provide its
services, the impact of government regulations, patent protection
on the Company's proprietary technology, product liability
exposure, uncertainty of market acceptance, competition,
technological change, and other risk factors. In such instances,
actual results could differ materially as a result of a variety of
factors, including the risks associated with the effect of changing
economic conditions and other risk factors detailed in the
Company's Securities and Exchange Commission filings.